---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023349"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:00:15.470481+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology granted European patent covering ateganosine-based telomere-targeting anticancer therapy

## Summary
- European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.
- Patent titled 'Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere'; invented by CSO Sergei Gryaznov and SAB member Jerry Shay.
- MAIA's global IP portfolio now includes 10 issued patents worldwide, validated in 19 European countries, and 24 pending applications.
- Next-generation telomere-targeting agents aim to improve specificity toward cancer cells and increase anticancer activity.

## SEC filing metadata
- accession: 0001641172-25-023349
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000164117225023349/0001641172-25-023349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000164117225023349/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023349
- JSON: https://secwatch.observer/filing/0001641172-25-023349.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.